RVXCF
Price:
$0.04
Market Cap:
$11.23M
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.[Read more]
Industry
Biotechnology
IPO Date
2009-02-13
Stock Exchange
PNK
Ticker
RVXCF
According to Resverlogix Corp.’s latest financial reports and current stock price. The company's current PE Ratio is -1.00. This represents a change of -41.07% compared to the average of -1.70 of the last 4 quarters.
The mean historical PE Ratio of Resverlogix Corp. over the last ten years is -3.08. The current -1.00 PE Ratio has changed 3.14% with respect to the historical average. Over the past ten years (40 quarters), RVXCF's PE Ratio was at its highest in in the March 2021 quarter at 1.99K. The PE Ratio was at its lowest in in the June 2022 quarter at -29.80.
Average
-3.08
Median
-3.37
Minimum
-10.49
Maximum
5.75
Discovering the peaks and valleys of Resverlogix Corp. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.05%
Maximum Annual PE Ratio = 5.75
Minimum Annual Increase = -465.88%
Minimum Annual PE Ratio = -10.49
Year | PE Ratio | Change |
---|---|---|
2022 | -7.35 | 89.67% |
2021 | -3.87 | -465.88% |
2020 | 1.06 | -130.71% |
2019 | -3.45 | 46.08% |
2018 | -2.36 | -28.11% |
2017 | -3.28 | -44.74% |
2016 | -5.94 | -43.38% |
2015 | -10.49 | 1.05% |
2014 | -0.91 | -115.80% |
2013 | 5.75 | 7.94% |
The current PE Ratio of Resverlogix Corp. (RVXCF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.39
5-year avg
-3.19
10-year avg
-3.08
Resverlogix Corp.’s PE Ratio is greater than Cellectis S.A. (-2.93), greater than Biotron Limited (-4.24), greater than Small Pharma Inc. (-2.20), greater than Covalon Technologies Ltd. (-111.00), less than Bioasis Technologies Inc. (0), greater than Fennec Pharmaceuticals Inc. (-120.74), greater than Biohaven Pharmaceutical Holding Company Ltd. (-5.35), greater than ImmunityBio, Inc. (-6.04), greater than Cadrenal Therapeutics, Inc. Common Stock (-2.18), greater than Foghorn Therapeutics Inc. (-5.38), less than Comera Life Sciences Holdings, Inc. (-0.00), less than Coya Therapeutics, Inc. (0), greater than NewAmsterdam Pharma Company N.V. (-9.25), greater than Centessa Pharmaceuticals plc (-10.06), greater than Eliem Therapeutics, Inc. (-12.26), greater than Inhibrx Biosciences, Inc. (-2.42), less than Merrimack Pharmaceuticals, Inc. (0.13), greater than Celcuity Inc. (-8.92), greater than Enliven Therapeutics, Inc. (-6.01), greater than null (-13.90),
Company | PE Ratio | Market cap |
---|---|---|
-2.93 | $183.12M | |
-4.24 | $11.30M | |
-2.20 | $37.51M | |
-111.00 | $72.60M | |
0 | $284.08K | |
-120.74 | $145.92M | |
-5.35 | $4.60B | |
-6.04 | $3.55B | |
-2.18 | $24.86M | |
-5.38 | $435.85M | |
-0.00 | $9.22K | |
0 | $108.60M | |
-9.25 | $1.87B | |
-10.06 | $2.06B | |
-12.26 | $342.68M | |
-2.42 | $203.82M | |
0.13 | $223.97M | |
-8.92 | $489.74M | |
-6.01 | $1.20B | |
-13.90 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Resverlogix Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Resverlogix Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Resverlogix Corp.'s PE Ratio?
How is the PE Ratio calculated for Resverlogix Corp. (RVXCF)?
What is the highest PE Ratio for Resverlogix Corp. (RVXCF)?
What is the 3-year average PE Ratio for Resverlogix Corp. (RVXCF)?
What is the 5-year average PE Ratio for Resverlogix Corp. (RVXCF)?
How does the current PE Ratio for Resverlogix Corp. (RVXCF) compare to its historical average?